エピソード

  • 70% Remission for Postpartum Depression? The Psychedelic Breakthrough

    70% Remission for Postpartum Depression? The Psychedelic Breakthrough
    2026/04/30
    Postpartum depression treatment advances with psychedelic therapy. Greg Mayes of Reunion Neuroscience discusses luvesilocin drug development. This episode explores how shorter-acting psilocybin analogs offer new hope for mothers. Greg highlights the success of the RECONNECT study and the path to FDA breakthrough designation.
    続きを読む 一部表示
    36 分
  • Why Psychiatry Is Finally Breaking Free From Dopamine

    Why Psychiatry Is Finally Breaking Free From Dopamine
    2026/04/15
    In this episode of Power to the Patients, host Brandon Li sits down with Ken Kramer, PhD, Vice President and Head of Neuropsychiatry Medical Affairs at Bristol Myers Squibb, to explore why psychiatry has lagged behind other therapeutic areas and what’s finally changing. Kramer explains how decades of reliance on dopamine-based antipsychotics shaped treatment, and why new mechanisms like muscarinic agonism are opening the door to safer, more effective options for patients with schizophrenia.
    続きを読む 一部表示
    29 分
  • Precision Medicine Got Kidney Disease Wrong—Until Now

    Precision Medicine Got Kidney Disease Wrong—Until Now
    2026/04/01
    Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.
    続きを読む 一部表示
    42 分
  • Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible

    Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
    2026/03/18
    In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s.
    続きを読む 一部表示
    38 分
  • Why Serotonin Isn’t Outdated, Our Thinking Is

    Why Serotonin Isn’t Outdated, Our Thinking Is
    2026/03/11
    In this episode of Power to the Patients, host Brandon Li sits down with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, to challenge some of psychiatry’s most deeply held assumptions. Dr. Seld explains why clinical novelty, not mechanistic novelty, is what truly matters to patients, and how amplifying serotonin synthesis may offer a safer, more scalable path forward for treating depression and OCD.
    続きを読む 一部表示
    41 分
  • Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian

    Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
    2026/02/25
    In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments.
    続きを読む 一部表示
    40 分
  • Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health

    Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health
    2026/02/18
    In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way.
    続きを読む 一部表示
    34 分
  • The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients

    The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients
    2026/02/11
    In this episode of Power to the Patients, Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix, to explore how synaptic restoration is revolutionizing treatment for Fragile X, autism, ALS, Alzheimer's, and schizophrenia. From his decades of clinical experience and pioneering work at Spinogenix, Dr. Erickson shares the science behind restoring brain connectivity, the bold early results that surprised even experts, and why this approach could transform outcomes for patients with devastating neurological disorders.
    続きを読む 一部表示
    39 分